Trials / Completed
CompletedNCT05829551
The Safety, Tolerability and Pharmacokinetics Study of RAY1216 in Healthy Adult Participants
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of RAY1216 and the Effect of Food on RAY1216 Pharmacokinetics in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is double-blind,randomized, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety, tolerability and drug-drug interaction of RAY1216, and the effect of food on RAY1216 Pharmacokinetics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RAY1216 dose 1 | RAY1216 dose 1 or Placebo |
| DRUG | RAY1216 dose 2 | RAY1216 dose 2 or Placebo |
| DRUG | RAY1216 dose 3 | RAY1216 dose 3 or Placebo |
| DRUG | RAY1216 dose 4 &ritonavir | RAY1216 dose 4 \&ritonavir or Placebo |
| DRUG | RAY1216 dose 5 | RAY1216 dose 5 or Placebo |
| DRUG | RAY1216 dose 6 | RAY1216 dose 6 or Placebo |
| DRUG | RAY1216 dose 7 | RAY1216 dose 7 or Placebo |
| DRUG | RAY1216 dose 8 | RAY1216 dose 8 or Placebo |
| DRUG | RAY1216 dose 9 | RAY1216 dose 9 or Placebo with high fat meal |
| DRUG | RAY1216 dose 10 | RAY1216 dose 10 or Placebo with high fat meal |
Timeline
- Start date
- 2022-05-20
- Primary completion
- 2022-08-12
- Completion
- 2022-08-12
- First posted
- 2023-04-25
- Last updated
- 2023-04-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05829551. Inclusion in this directory is not an endorsement.